Substance Use Disorders 101: The Overview
In partnership with AMERSA, this shortened version of Grayken TTA’s Addiction 101 training provides an overview of the disease model of addiction, the overdose epidemic, stigma, and evidence-based treatments for persons with substance use disorder. Estimated time to complete: 30 minutes. CEs: CME (0.50); Nursing (0.50); LADC/CADC (0.50); RC (0.50).
Funding for this initiative was made possible (in part) by 1H79TI085588-02 from SAMHSA. The views expressed by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Buprenorphine Extended-Release Injection: An Instructional Guide
This instructional video provides a comprehensive overview of extended-release injectable buprenorphine for the treatment of opioid use disorder, focusing on the two FDA-approved forms: Sublocade® and Brixadi®. The video includes step-by-step demonstrations of how to properly prepare and administer each formulation. Viewers will learn about proper site selection, needle placement, and post-injection care. Additionally, safety protocols and potential side effects are covered.
Funding was made possible through grants from the Bureau of Addiction Services at the Massachusetts Department of Public Health. In addition, funding for this initiative was made possible (in part) by 1H79TI085588-02 from SAMHSA. The views expressed by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Medication Opioid Use Disorder Tool Kit for Peer Recovery Specialists
This toolkit is a resource for Peer Recovery Specialists (PRSs) to feel equipped to discuss Medications for Opioid Use Disorder (MOUD) with providers, people seeking recovery, and others with questions about this treatment option.
This publication has been made possible by funding from the Opioid Response Network (ORN). Funding was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The contents of this document are solely the responsibility of the authors and do not necessarily represent the official views of SAMHSA or the U.S. Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by
the U.S. Government.
Special thanks to contributing authors White AH, Garets M, Foringer J, Dahlem CH, Beck MC, Soske J, Barnes J, Eckhardt D, Feldstein K, O’Donnell N, Britton J, Lugo H, Filimoeatu L, Cochran G.
The 2022 Practice Question Supplement for the CARN and CARN-AP Examinations
This publication has been made possible by funding from the Opioid Response Network (ORN). Funding was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The contents of this document are solely the responsibility of the authors and do not necessarily represent the official views of SAMHSA or the U.S. Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Click here to access this resource
AMERSA is Proud to Partner with Providers’ Clinical Support System (PCSS) and Opioid Response Network (ORN)
Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Providers Clinical Support System
www.pcssNOW.org
Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Opiod Response Network
www.opioidresponsenetwork.org
See more videos – from our members!
Other Resources
Alcohol and Pregnancy: The More You Know
Learn about Prenatal Alcohol Exposure, Fetal Alcohol Spectrum Disorders (FASDs), and how to talk to your patients about unhealthy alcohol use in this 3-part podcast.
https://cme.bu.edu/fasdpodcast
Addiction Technology Transfer Network
http://www.attc.org/home/
American Academy of Addiction Psychiatry (AAAP)
http://www.aaap.org/
Clinical Trials Network
http://www.drugabuse.gov/about-nida/organization/cctn/ctn
National Institute on Drug Abuse (NIDA)
http://www.drugabuse.gov/
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
http://www.niaaa.nih.gov
Office of National Drug Control Policy
https://www.whitehouse.gov/ondcp
Substance Abuse and Mental Health Services Administration (SAMHSA)
http://www.samhsa.gov/